Camilla Chong, MD, Chief Medical Officer of InflaRx, commented: “We are pleased to have started our Phase 2a trial for INF904 with the first patient dosed at one of our U.S. sites, and I am very proud ...
16h
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback